Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 321

1.

Anti-angiogenic activity of a small molecule STAT3 inhibitor LLL12.

Bid HK, Oswald D, Li C, London CA, Lin J, Houghton PJ.

PLoS One. 2012;7(4):e35513. doi: 10.1371/journal.pone.0035513. Epub 2012 Apr 17.

2.

Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice.

Onimoe GI, Liu A, Lin L, Wei CC, Schwartz EB, Bhasin D, Li C, Fuchs JR, Li PK, Houghton P, Termuhlen A, Gross T, Lin J.

Invest New Drugs. 2012 Jun;30(3):916-26. doi: 10.1007/s10637-011-9645-1. Epub 2011 Feb 22.

PMID:
21340507
3.

Inhibition of STAT3 signaling pathway by nitidine chloride suppressed the angiogenesis and growth of human gastric cancer.

Chen J, Wang J, Lin L, He L, Wu Y, Zhang L, Yi Z, Chen Y, Pang X, Liu M.

Mol Cancer Ther. 2012 Feb;11(2):277-87. doi: 10.1158/1535-7163.MCT-11-0648. Epub 2011 Dec 27.

4.

The small molecule, LLL12, inhibits STAT3 phosphorylation and induces apoptosis in medulloblastoma and glioblastoma cells.

Ball S, Li C, Li PK, Lin J.

PLoS One. 2011 Apr 19;6(4):e18820. doi: 10.1371/journal.pone.0018820.

5.

Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.

Huang SW, Lien JC, Kuo SC, Huang TF.

Carcinogenesis. 2012 May;33(5):1022-30. doi: 10.1093/carcin/bgs127. Epub 2012 Mar 20.

PMID:
22436611
6.

CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.

Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.

Cancer Res. 2003 Sep 15;63(18):5978-91. Erratum in: Cancer Res. 2003 Nov 1;63(21):7543.

7.

SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.

Cao ZX, Zheng RL, Lin HJ, Luo SD, Zhou Y, Xu YZ, Zeng XX, Wang Z, Zhou LN, Mao YQ, Yang L, Wei YQ, Yu LT, Yang SY, Zhao YL.

Cell Physiol Biochem. 2011;27(5):565-74. doi: 10.1159/000329978. Epub 2011 Jun 15.

8.

LLL12, a novel small inhibitor targeting STAT3 for hepatocellular carcinoma therapy.

Zuo M, Li C, Lin J, Javle M.

Oncotarget. 2015 May 10;6(13):10940-9.

9.

Indirubin derivative E804 inhibits angiogenesis.

Shin EK, Kim JK.

BMC Cancer. 2012 May 3;12:164. doi: 10.1186/1471-2407-12-164.

10.

Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model.

Kim CK, Joe YA, Lee SK, Kim EK, O E, Kim HK, Oh BJ, Hong SH, Hong YK.

Cancer Lett. 2010 Feb 28;288(2):251-60. doi: 10.1016/j.canlet.2009.07.008. Epub 2009 Aug 6.

PMID:
19664879
11.

A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells.

Lin L, Hutzen B, Li PK, Ball S, Zuo M, DeAngelis S, Foust E, Sobo M, Friedman L, Bhasin D, Cen L, Li C, Lin J.

Neoplasia. 2010 Jan;12(1):39-50.

12.

Fisetin inhibits various attributes of angiogenesis in vitro and in vivo--implications for angioprevention.

Bhat TA, Nambiar D, Pal A, Agarwal R, Singh RP.

Carcinogenesis. 2012 Feb;33(2):385-93. doi: 10.1093/carcin/bgr282. Epub 2011 Dec 1.

PMID:
22139440
13.

A small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells.

Lin L, Benson DM Jr, DeAngelis S, Bakan CE, Li PK, Li C, Lin J.

Int J Cancer. 2012 Mar 15;130(6):1459-69. doi: 10.1002/ijc.26152. Epub 2011 Aug 26.

14.

Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.

Li X, Wang X, Ye H, Peng A, Chen L.

Cancer Chemother Pharmacol. 2012 Sep;70(3):425-37. doi: 10.1007/s00280-012-1923-x. Epub 2012 Jul 20.

PMID:
22814678
15.

Luteolin inhibits human prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis.

Pratheeshkumar P, Son YO, Budhraja A, Wang X, Ding S, Wang L, Hitron A, Lee JC, Kim D, Divya SP, Chen G, Zhang Z, Luo J, Shi X.

PLoS One. 2012;7(12):e52279. doi: 10.1371/journal.pone.0052279. Epub 2012 Dec 31.

16.

Biologic activity of the novel small molecule STAT3 inhibitor LLL12 against canine osteosarcoma cell lines.

Couto JI, Bear MD, Lin J, Pennel M, Kulp SK, Kisseberth WC, London CA.

BMC Vet Res. 2012 Dec 17;8:244. doi: 10.1186/1746-6148-8-244.

17.

Two small molecule compounds, LLL12 and FLLL32, exhibit potent inhibitory activity on STAT3 in human rhabdomyosarcoma cells.

Wei CC, Ball S, Lin L, Liu A, Fuchs JR, Li PK, Li C, Lin J.

Int J Oncol. 2011 Jan;38(1):279-85.

PMID:
21109950
18.

STAT1 activation by venous malformations mutant Tie2-R849W antagonizes VEGF-A-mediated angiogenic response partly via reduced bFGF production.

Huang YH, Wu MP, Pan SC, Su WC, Chen YW, Wu LW.

Angiogenesis. 2013 Jan;16(1):207-22. doi: 10.1007/s10456-012-9313-x. Epub 2012 Oct 21.

PMID:
23086340
19.

(-)-Epigallocatechin-3-gallate inhibits growth of gastric cancer by reducing VEGF production and angiogenesis.

Zhu BH, Zhan WH, Li ZR, Wang Z, He YL, Peng JS, Cai SR, Ma JP, Zhang CH.

World J Gastroenterol. 2007 Feb 28;13(8):1162-9.

20.

Inhibition of metastasis, angiogenesis, and tumor growth by Chinese herbal cocktail Tien-Hsien Liquid.

Chia JS, Du JL, Hsu WB, Sun A, Chiang CP, Wang WB.

BMC Cancer. 2010 Apr 30;10:175. doi: 10.1186/1471-2407-10-175.

Supplemental Content

Support Center